ARC-20: A phase 1 dose-escalation and dose-expansion study to investigate the safety, tolerability, and pharmacology of HIF-2a inhibitor AB521 monotherapy in patients with clear cell renal cell carcinoma and other solid tumors.
AB-521
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: ARC-20: A phase 1 dose-escalation and dose-expansion study to investigate the safety, tolerability, and pharmacology of HIF-2a inhibitor AB521 monotherapy in patients with clear cell renal cell carcinoma and other solid tumors. ### Output: AB-521